COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Jan 11, 2025 8:18am

66 Views

Post# 36399246

New Avenanthramide study

The study on avenanthramides (AVNs) ameliorating insulin resistance in HepG2 cells has significant implications for Ceapro's pharma-grade avenanthramide pill clinical trial:

Mechanism of action: The research demonstrates that AVNs can increase glucose uptake, enhance glycogen content, and regulate glucose metabolism by activating the IRS-1/PI3K/Akt pathway and inhibiting gluconeogenesis
2
. This provides a potential mechanism of action for the avenanthramide tablets being tested in Ceapro's clinical trial.
Potential applications: The study suggests AVNs could be effective in managing conditions related to inflammation and insulin resistance, aligning with Ceapro's focus on inflammation-based diseases
1

3
.
Dosage insights: The study used 100 μM concentrations of AVNs A, B, and C, which increased glucose uptake by over 50% compared to FFA treatment alone
2
. Ceapro's clinical trial is testing doses ranging from 30mg to 960mg
1

3
. The clinical trial doses are significantly higher, with the highest dose being 9.6 times (960mg / 100mg) greater than the lowest dose.

The research is compelling when combined with other studies and ongoing clinical trials:

Consistency with previous findings: The results align with earlier research showing AVNs' benefits in preventing inflammation, cancer, and cardiovascular diseases
2
.
Clinical trial progress: Ceapro's ongoing Phase 1-2a trial has already begun dosing patients, providing real-world validation of the preclinical findings
5

9
.
Broader applications: The potential indications for Ceapro's avenanthramide include vascular disease, atherosclerosis, diabetes, exercise-induced inflammation, lung inflammation, and possibly cardiovascular pathology associated with COVID-19
1

3
.
Regulatory support: Health Canada's approval for the clinical trial indicates regulatory bodies see merit in pursuing AVNs as a potential therapeutic
1

7
.
Study design: The AvenActive trial's comprehensive design, including both single and multiple ascending dose arms, will provide valuable data on safety, tolerability, and pharmacokinetics
5

9
.

This combination of preclinical mechanistic insights, ongoing clinical trials, and regulatory support makes the research on avenanthramides highly compelling for their potential as a novel therapeutic agent, particularly in the context of inflammation-based diseases.